Extensions and applications of CompARE : web platform to select the primary endpoint in a randomized clinical trial by Gómez Mateu, Moisés & Gómez Melis, Guadalupe
357
42. EXTENSIONS AND APPLICATIONS OF COMPARE: WEB 
PLATFORM TO SELECT THE PRIMARY ENDPOINT 
IN A RANDOMIZED CLINICAL TRIAL
M. Gómez-Mateu and G. Gómez Melis
Universitat Politècnica de Catalunya, Department of Statistics 
and Operations Research, Spain,
moises.gomez.mateu@upc.edu
ABSTRACT
We present CompARE, a web platform that computes how more efficient is to use a 
composite endpoint instead of one of its components. CompARE is based on the 
Asymptotic Relative Efficiency (ARE) method developed by Gómez and Lagakos. 
Users interact with CompARE through HTML form pages and no knowledge of R is 
needed. A list of candidate endpoints, anticipatable probabilities and hazard ratios 
are required to use CompARE. Results are shown immediately through plots, text 
and tables. We present advanced capabilities of CompARE such as assigning 
probabilities and hazard ratios to combinations of several endpoints (relevant or ad-
ditional).
1. INTRODUCTION
Conclusions from randomized clinical trials (RCTs) rely on its primary endpoint cho-
sen at the design stage of the study. In order to provide clinical evidence related to 
the primary objective of the trial the selection of the primary endpoint is of outmost 
importance.
Composite endpoints (CEs) consisting of the union of two or more outcomes are of-
ten used as the primary endpoint in RCTs. For instance, in time-to-event studies, 
time to MACE is a CE generally defined as the union of cardiovascular death, 
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reinfarction, target vessel revascularization and stroke. Pros and cons on the use of 
CEs have been extensively discussed in the literature. From a medical perspective, 
the use of CEs allows to combine multiple measurements, avoiding the need to 
choose a single outcome as primary endpoint. However, some cautions have to be 
considered when defining a composite endpoint. A CE should only be used if the in-
dividual components are clinically meaningful and of similar importance to the pa-
tient, the expected effects on each component are similar based on biological plau-
sibility, and the clinically more important components do not affect negatively 
(Ferreira-González et al., 2007). Otherwise, the use of the CE is questionable and 
may lead to misleading conclusions. From a statistical point of view, the rationale for 
considering a CE, other than multiplicity, is the likely reduction of the sample size 
needed to achieve a desired statistical power for a given significance level, as a re-
sult of increasing the event rate to attain a predefined treatment effect. Nevertheless, 
it has been discussed and shown in Gómez and Lagakos (2013), that adding inap-
propriate components to the relevant endpoint might actually lead to a loss of power 
to detect the true treatment differences.
2. THE ARE METHOD TO CHOOSE THE PRIMARY ENDPOINT
Gómez and Lagakos (2013) develop a statistical methodology that helps to decide 
between using a Relevant endpoint εR instead of a composite endpoint, consisting of 
the union of εR plus another additional endpoint εA, to evaluate the effect of a treat-
ment. Their strategy is based on the value of the asymptotic relative efficiency (ARE).
The ARE relates the efficiency of using the logrank test ZR based on εR versus the 
efficiency of the logrank test Z* based on the CE. It can be shown that ZR and Z* are 
asymptotically N (0, 1) under the null hypothesis of no treatment effect and asymp-
totically N (μR , 1) and N (μ* , 1), respectively, under a sequence of contiguous alterna-
tives to the null hypothesis. Under these conditions, ARE(Z*, ZR) = (μ /μ )2. The com-
posite endpoint will be advisable to use as primary endpoint whenever the ARE(Z*, 
ZR ) > 1. Otherwise, εR will be considered the best choice.
We assume that: i) the end-of-study censoring is the only non-informative censoring 
cause for both groups; ii) the hazard ratios H RR and H RA for εR and εA, respectively, 
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are constant; iii) marginal Weibull distributions for the time TR and TA to εR and εA, 
respectively; and iv) Frank’s copula binding the marginals (TR, TA) through Speraman 
correlation ρ. Under these assumptions, when the additional endpoint εA does not 
include death, the expression of the ARE is given by:
where pR and p* are the probabilities of observing εR and ε* in control group, respec-
tively; and λ*(0)(t) and λ*(1)(t) are the hazard functions of the times T*(0) and T*(1) to the 
composite endpoint for each group, respectively. The ARE expression in either cen-
soring case is expressed in terms of the following interpretable parameters:
• Probabilities pR, pA of observing εR, εA, respectively, in control group,
• relative treatment effects given by the hazard ratios H RR, H RA, and
• Spearman’s correlation coefficient ρ between TR and TA.
The ARE as ratio of sample sizes
If we were to test H0 versus Ha with two different test statistics Sn and Tm , the asymp-
totic relative efficiency would be defined as the ratio m/n, where n and m are the re-
quired sample sizes for Sn and Tm, respectively, to attain the same power for a given 
significance level.
In our setup we have two different set of hypotheses: H0 versus Ha testing the treat-
ment effect on εR and H0* versus Ha* testing the treatment effect on 0 a εR. Gómez and 
Lagakos prove that the ARE can be interpreted as nR /n*, where nR and n* stand for the 
required sample sizes needed when using the Relevant endpoint or the composite 
endpoint, respectively.
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3. CompARE: A TOOL TO CHOOSE THE PRIMARY ENDPOINT IN A RCT
With the aim of making the ARE method widely applicable to the scientific commu-
nity, a free web-based platform called CompARE has been created.
CompARE provides a tool to compute the ARE among several subsets of relevant 
components. It is of great help when planning a clinical trial since it quantifies how 
efficient is a relevant subset of outcomes respect to a larger subset. CompARE is a 
friendly tool, based on the free software Tiki Wiki CMS/Goupware. Although it is in-
ternally programmed in R, users do not need knowledge of R, neither to have R in-
stalled in their computer. By means of web-page forms, users can easily introduce 
the required information, step by step. This information is saved and executed by the 
system, returning ad-hoc results depending on each case.
ARE values are calculated from the anticipated information of the probabilities and 
hazard ratios pR, pA, H RR and H RA by means of an input grid. Moderate correlations 
ρ and exponential distributions are considered by default. Other advanced options 
are available such as Weibull distributions with decreasing or increasing hazard 
rates or different correlations.
Results from CompARE are shown by means of summary tables and plots. Outputs 
combining several H RA together with different correlation values are of great help 
to understand the role that the Additional endpoint plays (see Figure 1). Additionally, 
survivals and hazard ratios for εR, εA and CE are depicted. A history table saves each 
result to compare previous analyses. Moreover, conclusions and recommendations 
are given in written form as an aid. CompARE is currently accessible as a beta ver-
sion on the following website (http://composite.upc.edu/CompARE).
4. APPLICATIONS TO THE CARDIOVASCULAR RESEARCH AREA
The ARE method has been applied to the cardiovascular research area (Gómez, 
Gómez-Mateu and Dafni, 2014), where a set of general recommendations are re-
ported from RCTs published in 2008. General guidelines are provided based on the 
frequencies of observation and treatment effects of the Relevant and the Additional 
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endpoints. In the following subsection we illustrate some of the CompARE capabili-
ties by means of a real RCT.
Figure 1. ARE values combining different values of the hazard ratio H RA of the Additional endpoint 
εA and correlation between times to the Relevant endpoint εR and εA. Fixed parameters: 
probabilities pR and pA of observing εR and εA, respectively, in control group; and hazard ratio H RR 
of εR.
A case study: The LIFE trial
The Losartan Intervention For Endpoint reduction in hypertension study (LIFE) trial 
(Dahlöf et al., 2002) was performed to test the efficacy of Losartan-based antihyper-
tensive treatment in patients with hypertension. The primary composite endpoint 
(CE) was composed by cardiovascular death, myocardial infarction and stroke. 
Cardiovascular death + myocardial infarction are considered the most clinically im-
portant components (Sankoh et al., 2014), and hence we refer to them as the 
Relevant endpoint εR, and stroke as the Additional endpoint εA. Significant results 
were achieved using the CE, consequence of the significant effect on stroke (see 
Table 1).
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Endpoint Type Control treatmentProbability (n)
Hazard ratio
(CI, 95%) p-value
Cardiovasc. mortality εr1 0.05 (234) 0.89 (0.73 – 1.07) 0.206
Myocardial infarction εr2 0.04 (188) 1.07 (0.88 – 1.31) 0.491
Stroke εA 0.07 (309) 0.75 (0.63 – 0.89) 0.001
εr1 U εr1 U εA Composite 0.13 (588) 0.87 (0.77 – 0.98) 0.021
Table 1. Summary of the results from the LIFE trial. εr1 and εr2 stand for Relevant endpoint component 1 
and 2 respectively; εA stands for Additional endpoint; and CI stands for the confidence interval.
We present an ARE study based on two different situations. In both we will assume 
a probability of observing εR and εA in control group of pR = 0.06 and pA = 0.07, respec-
tively, as feasible anticipated values of this study.
If we anticipate relative treatment effects as reported in the LIFE study, that is 
H RR = 0.89 for the relevant endpoint and H RA = 0.75 for the additional endpoint, we 
would have recommended to use the composite endpoint, as they did. Indeed, as 
Figure 1 (left) shows, the ARE value is always greater than 1 for every possible 
correlation between εR and εA.
However, if the expected relative treatment effect on the relevant endpoint would 
have been stronger, for instance H RR = 0.76, then the CE would have not been al-
ways advised. As shown in Figure 1 (right), we would conclude that using εR as pri-
mary endpoint would be the best recommendation whenever the relative treatment 
effect of the Losartan intervention on stroke was larger than 0.9. On the other hand, 
adding stroke to the primary endpoint would be advisable if the relative treatment 
effect was at most 0.8. For the situations where the relative treatment effect on 
stroke were expected to be between 0.8 and 0.9 special attention should be paid at 
the correlation between cardiovascular death + myocardial infarction and stroke.
5. PRACTICAL ISSUES TO ASSIGN ANTICIPATABLE COMBINED PROBABILITIES 
AND HAZARD RATIOS
The ARE method is based on the assumption that, even when the Relevant endpoint 
consist of several components, both combined probability and hazard ratio can be 
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anticipated by researchers (analogously, for the Additional endpoint). In some occa-
sions trialists might anticipate these probabilities and hazard ratios for each one of 
the components. In what follows, we describe how to compute the combined 
probability and hazard ratio and discuss how it is implemented in CompARE.
Following Bahadur (1961), the combined probability pR can be computed in terms of 
the probability components pR1 and pR2 of observing the relevant components εR1 and 
εR2 in the control group, respectively, for a given correlation δr between endpoints 
(more than two components can also be considered). Concerning the combined 
H RR, the exact value is in terms not only of the hazard ratios H Rr1 and H Rr2 of εR1 
and εR2, respectively, but also depends on the probabilities pr1 and pr2, the marginal 
laws of each component, the correlation and the joint distribution between compo-
nents. Furthermore, H RR does not have to be constant even though H Rr1 and H Rr1 
are constant.
CompARE implements, as advanced options, the possibility of assigning a value for 
pR and for H RR. In particular, whenever the correlation between εR1 and εR2 is un-
known, the user can choose between any value within the following bounds: max(pr1, 
pr2) and pR1 + pR2 (see Figure 2). For the combined H RR a set of possible values is as 
well proposed.
Figure 2. Boundaries for the combined probability pR and hazard ratio H RR in terms of Pearson’s 
correlation δr and Spearman’s correlation ρr, respectively. pr1 and pr2 stand for the marginal probability 
of observing the Relevant component εr1 and εr2 in control group, respectively. H Rr1 and H Rr2 stands for 
the marginal hazard ratio of each component. Component parameter values are taken from the LIFE 
study.
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6. CONCLUDING REMARKS
This paper addresses the ARE method as an intuitive and interpretable way of com-
paring the efficiency of several endpoints, candidates for the primary endpoint of a 
RCT. We present as well CompARE, a web platform that performs all the ARE com-
putations, which can be freely accessed and is friendly to use. Ongoing research in-
clude several extensions of CompARE :
1. Sample size computation based on the anticipatable parameters.
2. Combined probabilities and hazard ratios.
3. Computations when both εR and εA include death.
4. Different copulas other than Frank’s.
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